Elite in Monilethrix

Yutaka Shimomura

Ube, JP 
Elite in Monilethrix
Ube, JP 
OverviewLocationsClinical Research

Overview

Yutaka Shimomura practices in Ube, Japan. Mr. Shimomura is rated as an Elite expert by MediFind in the treatment of Monilethrix. His top areas of expertise are Monilethrix, Autosomal Recessive Hypotrichosis, Trichorhinophalangeal Syndrome Type 2, Woolly Hair Syndrome, and Pancreaticoduodenectomy.

His clinical research consists of co-authoring 149 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Monilethrix.

Gender
Male

Locations

Ube, Japan
Other Locations
Yamaguchi, Japan
Niigata, Japan
Chuo, 9518510, Japan
Nagakute, Japan
Asahimachi, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

149 Total Publications

Clinical improvement of salt-and-pepper skin changes in juvenile systemic sclerosis using mycophenolate mofetil after intravenous methylprednisolone: a 3-year follow-up.
Clinical improvement of salt-and-pepper skin changes in juvenile systemic sclerosis using mycophenolate mofetil after intravenous methylprednisolone: a 3-year follow-up.
Journal: Immunological medicine
Published: October 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Shimomura's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 24 Advanced Conditions
View All 61 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile